⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990667 | 0.93 | L3MBTL1 (0.46) | — | |
| SCHEMBL9321537 | 0.91 | L3MBTL1 (0.49) | — | |
| SCHEMBL7341152 | 0.87 | PIK3CD (0.47) | — | |
| SCHEMBL261644 | 0.85 | PIK3CD (0.58) | — | |
| SCHEMBL7622769 | 0.85 | ADRA1B (0.46) | — | |
| SCHEMBL7622224 | 0.81 | — | — | |
| SCHEMBL5424673 | 0.81 | PIK3CD (0.54) | — | |
| SCHEMBL10978509 | 0.81 | L3MBTL1 (0.43) | — | |
| SCHEMBL7625589 | 0.79 | L3MBTL1 (0.42) | — | |
| SCHEMBL729385 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2025119893-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4469164-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024169914-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-08-22 | — | — | WO | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-110831942-B | Fused indazolopyridinone compounds as antiviral agents | 诺华股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11420963-B2 | Rebamipide prodrugs, preparation method and use thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2022-08-23 | — | — | US | disclosed |
| WO-2009139834-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| WO-2009055828-A1 | NEW TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| CN-101208094-A | Pharmacokinetic improved compounds | SURFACE LOGIX INC (US) | 2008-06-25 | — | — | CN | disclosed |
| EP-1865958-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | Surface Logix, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105081-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-0307423-A4 | MANUFACTURE OF HALOALKYL LACTAMS | — | 1990-12-05 | — | — | EP | disclosed |
| EP-0307423-A1 | MANUFACTURE OF HALOALKYL LACTAMS | GAF CHEMICALS CORPORATION (US) | 1989-03-22 | — | — | EP | disclosed |
| US-4792604-A | Manufacture of haloalkyl lactams | GAF CORPORATION (US) | 1988-12-20 | — | — | US | disclosed |
| WO-1988007039-A1 | MANUFACTURE OF HALOALKYL LACTAMS | GAF CORPORATION (US) | 1988-09-22 | — | — | WO | disclosed |